logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • Antisense Oligonucleotide class drugs

    FiltersReset Filters
    7 results

    • amondys 45

      (casimersen)
      Sarepta Therapeutics, Inc.
      Usage: AMONDYS 45 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene suitable for exon 45 skipping. Its approval is based on increased dystrophin production in skeletal muscle, with continued approval dependent on confirmatory trial results.

    • exondys 51

      (eteplirsen)
      Sarepta Therapeutics, Inc.
      Usage: EXONDYS 51 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene suitable for exon 51 skipping. Its approval is based on observed increases in dystrophin in skeletal muscle, pending further verification of clinical benefit in ongoing trials.

    • qalsody

      (tofersen)
      Biogen Inc.
      Usage: QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults with a superoxide dismutase 1 (SOD1) gene mutation. Approval is based on reduced plasma neurofilament light chain (NfL) levels, with continued approval pending verification of clinical benefit from further trials.

    • spinraza

      (Nusinersen)
      Biogen
      Usage: SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in both pediatric and adult patients.

    • tegsedi

      (inotersen)
      Akcea Therapeutics, Inc.
      Usage: TEGSEDI is indicated for treating the polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults.

    • vyondys 53

      (golodirsen)
      Sarepta Therapeutics, Inc.
      Usage: VYONDYS 53 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation suitable for exon 53 skipping. Approval is based on increased dystrophin production in skeletal muscle, with continued approval dependent on clinical benefit verification in further trials.

    • wainua

      (EPLONTERSEN)
      AstraZeneca Pharmaceuticals LP
      Usage: WAINUA is indicated for the treatment of polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults.